ホームMCPワークベンチSkills
ホームワークベンチ通知マイページ
llms.txt · MCPガイドプライバシーポリシー · 利用規約 · サポートv1.8.3
  1. ホーム
  2. /化合物

フルデオキシグルコース (18F)

Fludeoxyglucose (18F)

HCID 450503
反応を作成
印刷

データを補完しています。しばらくしてからページを更新すると最新の内容を表示できます

基本情報概要名称と識別子物性化学と産業関連反応化合物ノート
部分構造検索類似構造を探す

基本情報

CAS
105851-17-0
標準SMILES
OC[C@H]1O[C@H](O)[C@H]([18F])[C@@H](O)[C@@H]1O
InChIKey
ZCXUVYAZINUVJD-AHXZWLDOSA-N
分子式
C6H11FO5
平均分子量
181.15 g/mol
単同位体質量
181.061586

概要

2-deoxy-2-((18)F)fluoro-alpha-D-glucose is a 2-deoxy-2-((18)F)fluoro-D-glucopyranose and a 2-deoxy-2-fluoro-alpha-D-glucose.

名称と識別子

優先名称
Fludeoxyglucose (18F)
IUPAC
(2S,3R,4S,5S,6R)-3-(18F)fluoro-6-(hydroxymethyl)oxane-2,4,5-triol
現地名
フルデオキシグルコース (18F)
英語名
Fludeoxyglucose F 18
分子式
C6H11FO5
分子量
181.148

名称と別名

105851-17-0Fludeoxyglucose (18F)SBT3GBX27WF-18 FDGFludeoxyglucose (18F) [INN]UNII-SBT3GBX27W2-(Fluoro-18F)-2-deoxy-alpha-glucopyranosealpha-D-Glucopyranose, 2-deoxy-2-(fluoro-18F)-Fludeoxyglucose f 18 [USAN:USP](2S,3R,4S,5S,6R)-3-(18F)fluoranyl-6-(hydroxymethyl)oxane-2,4,5-triol2-Deoxy-2-fluoro-(sup 18)F-alpha-D-glucopyranosealpha-D-Glucopyranose, 2-deoxy-2-(fluoro-(sup 18)F)-
名称をさらに表示
2-デオキシ-2-(18F)フルオロ-α-D-グルコピラノース2-(18F)フルオロ-2-デオキシ-α-D-グルコピラノースフルデオキシグルコース (18F)フルデオキシグルコース (18F) (JAN)Fludeoxyglucose F 18Fluorodeoxyglucose F18Fludeoxyglucose (18F)-2-deoxy-2-((18)F)fluoro-alpha-D-glucose2-Deoxy-2-(18F)fluoro-α-D-glucopyranose2-(18F)Fluoro-2-deoxy-α-D-glucopyranose2-Deoxy-2-(fluoro-18F)-α-D-glucopyranose (ACI)2-(Fluoro-18F)-alpha-D-glucopyranose, Fludeoxyglucose (18F)
Fluorodeoxyglucose F 18[18F]FDGFlucisFludeoxyglucose-18FSCHEMBL135994Fludeoxyglucose F 18 (USP)(18)FDGFludeoxyglucose (18F); Fludeoxyglucose F 18; Fluorine F 18 Fluorodeoxyglucose

物性

構造計算による物性補完中

XLogP
-1.6
極性表面積
90.2 Ų
水素結合供与体数
4
水素結合受容体数
6
回転可能結合数
1
重原子数
12
形式電荷
0
複雑度
155

実験および物理化学的性質

DrugsPharmaceuticals -> Various

化学と産業

薬理情報

ATC Code · 2 件

V - Various

QV - Various

Protein BindingThe extent of binding of Fludeoxyglucose F 18 to plasma proteins is not known.
Pharmacodynamics · 1 件

Fludeoxyglucose F 18 Injection is rapidly distributed to all organs of the body after intravenous administration. After background clearance of Fludeoxyglucose F 18 Injection, optimal PET imaging is generally achieved between 30 to 40 minutes after administration. In cancer, the cells are generally characterized by enhanced glucose metabolism partially due to (1) an increase in the activity of glucose transporters, (2) an increased rate of phosphorylation activity, (3) a reduction of phosphatase activity or, (4) a dynamic alteration in the balance among all these processes. However, glucose metabolism of cancer as reflected by Fludeoxyglucose F 18 accumulation shows considerable variability. Depending on tumor type, stage, and location, Fludeoxyglucose F 18 accumulation may be increased, normal, or decreased. Also, inflammatory cells can have the same variability of uptake of Fludeoxyglucose F 18. In the heart, under normal aerobic conditions, the myocardium meets the bulk of its energy requirements by oxidizing free fatty acids. Most of the exogenous glucose taken up by the myocyte is converted into glycogen. However, under ischemic conditions, the oxidation of free fatty acids decreases, exogenous glucose becomes the preferred myocardial substrate, glycolysis is stimulated, and glucose taken up by the myocyte is metabolized immediately instead of being converted into glycogen. Under these conditions, phosphorylated Fludeoxyglucose F 18 accumulates in the myocyte and can be detected with PET imaging. Normally, the brain relies on anaerobic metabolism. In epilepsy, the glucose metabolism varies. Generally, during a seizure glucose metabolism increases. Interictally, the seizure focus tends to be hypometabolic.

Mechanism of Action · 1 件

Fludeoxyglucose F 18 is a glucose analog that concentrates in cells that rely upon glucose as an energy source, or in cells whose dependence on glucose increases under pathophysiological conditions. Fludeoxyglucose F 18 is transported through the cell membrane by facilitative glucose transporter proteins and is phosphorylated within the cell to [18F] FDG-6- phosphate by the enzyme hexokinase. Once phosphorylated it cannot exit until it is dephosphorylated by glucose-6-phosphatase. Therefore, within a given tissue or pathophysiological process, the retention and clearance of Fludeoxyglucose F 18 reflect a balance involving glucose transporter, hexokinase and glucose-6- phosphatase activities. When allowance is made for the kinetic differences between glucose and Fludeoxyglucose F 18 transport and phosphorylation (expressed as the “lumped constant” ratio), Fludeoxyglucose F 18 is used to assess glucose metabolism. In comparison to background activity of the specific organ or tissue type, regions of decreased or absent uptake of Fludeoxyglucose F 18 reflect the decrease or absence of glucose metabolism. Regions of increased uptake of Fludeoxyglucose F 18 reflect greater than normal rates of glucose metabolism.

関連反応

1 件
反応記録を作成
HRID 275523 の反応式
HRID 275523反応物として

化合物ノート

このページの内容基本情報概要名称と識別子物性化学と産業関連反応化合物ノート

データベース識別子

CAS
105851-17-0、63503-12-8
PubChem CID
450503
DTXSID
DTXSID50894178
ChEBI
CHEBI:31617
UNII
SBT3GBX27W
Nikkaji
J227.716F
Biological Half-Life10-13 minutes
Metabolism/Metabolites · 1 件

Fludeoxyglucose F 18 is transported into cells and phosphorylated to [18F]-FDG-6-phosphate at a rate proportional to the rate of glucose utilization within that tissue. [18F]-FDG-6-phosphate presumably is metabolized to 2-deoxy-2-[18F] fluoro-6-phospho-Dmannose ([18F]FDM-6-phosphate). Fludeoxyglucose F 18 Injection may contain several impurities (e.g., 2-deoxy-2-chloro-D-glucose (ClDG)). Biodistribution and metabolism of C1DG are presumed to be similar to Fludeoxyglucose F 18 and would be expected to result in intracellular formation of 2-deoxy-2-chloro-6-phospho-D-glucose (C1DG-6-phosphate) and 2-deoxy-2-chloro-6-phospho-D-mannose (ClDM-6-phosphate). The phosphorylated deoxyglucose compounds are dephosphorylated and the resulting compounds (FDG, FDM, C1DG, and ClDM) presumably leave cells by passive diffusion.

Absorption, Distribution and Excretion · 4 件

Fludeoxyglucose F 18 Injection is rapidly distributed to all organs of the body after intravenous administration.

Fludeoxyglucose F 18 is cleared from most tissues within 24 hours and can be eliminated from the body unchanged in the urine.

Fludeoxyglucose F 18 Injection is rapidly distributed to all organs of the body after intravenous administration.

Fludeoxyglucose F 18 and related compounds are cleared from non-cardiac tissues within 3 to 24 hours after administration. Clearance from the cardiac tissue may require more than 96 hours

応用分野

使用Diagnostic aid; radioactive agent.